NASDAQ: IMAImagenebio Inc Stock
$5.69-0.14 (-2.4%)
Updated Mar 19, 2026
IMA Price
$5.69
Fair Value Price
$4.96
Market Cap
$63.64M
52 Week Low
$5.35
52 Week High
$18.00
P/E
-0.59x
P/B
0.48x
P/S
42.01x
PEG
N/A
Dividend Yield
N/A
Revenue
$800.00k
Earnings
-$45.35M
Gross Margin
100%
Operating Margin
-5,712.38%
Profit Margin
-6,549.4%
Debt to Equity
0.15
Operating Cash Flow
-$48M
Beta
1.02
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IMA Overview
Ikena Oncology Incorporated is developing medicines tailored to patient groups with specific unmet needs. Its lead oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional factor in the Hippo signaling pathway. The company is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway, IK-175, an oral inhibitor of aryl hydrocarbon receptor, and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. Ikena Oncology was incorporated in 2016 and is headquartered in Boston, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IMA's potential to beat the market
- IMA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
IMA
RankedUnranked of 469
RankedUnranked of 469
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $32.78 | A | |
| $15.47 | A | |
| $181.80 | A |
Be the first to know about important IMA news, forecast changes, insider trades & much more!
IMA News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IMA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IMA ($5.69) is overvalued by 14.75% relative to our estimate of its Fair Value price of $4.96 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IMA ($5.69) is not significantly undervalued (14.75%) relative to our estimate of its Fair Value price of $4.96 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IMA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IMA due diligence checks available for Premium users.
Valuation
IMA fair value
Fair Value of IMA stock based on Discounted Cash Flow (DCF)
Price
$5.69
Fair Value
$4.96
Overvalued by
14.75%
IMA ($5.69) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IMA ($5.69) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IMA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IMA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.59x
Industry
28.51x
Market
31.34x
IMA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.48x
Industry
4.68x
IMA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IMA's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.9M
Profit Margin
0%
IMA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
IMA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$153.0M
Liabilities
$19.8M
Debt to equity
0.15
IMA's short-term assets ($140.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMA's short-term assets ($140.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IMA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.2M
Investing
-$1.4M
Financing
$0.0
IMA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IMA vs Biotech Stocks
Imagenebio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.